Positions

Overview

  • I have been conducting my research for more than 10 years with collaboration with Dr. Nabors, MD, who is the Director of the CCTS Clinical Research Unit and has more than 20 years of experience in science and glioma patient treatment. I am known in the international scientific community and have received several international scholarships and awards. I have successfully administered projects (research plan, staffing, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitors.Cancer Research2021
    2020 Elavl1 role in cell fusion and tunneling membrane nanotube formations with implication to treat glioma heterogeneityCancers.  12:1-18. 2020
    2018 Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment.Journal of Cancer Science and Therapy.  10:190-197. 2018
    2017 Hu antigen R (HuR) multimerization contributes to glioma disease progressionJournal of Biological Chemistry.  292:16999-17010. 2017
    2015 Growth factor dependent regulation of centrosome function and genomic instability by HuRBiomolecules.  5:263-281. 2015
    2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
    2012 Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome functionJournal of Biological Chemistry.  287:32277-32287. 2012
    2011 The RNA-binding protein HuR promotes glioma growth and treatment resistance 2011
    2009 Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factorJournal of Biological Chemistry.  284:33989-33998. 2009
    2004 Evidence that the TM1-TM2 loop contributes to the ρ1 GABA receptor poreJournal of Biological Chemistry.  279:20906-20914. 2004
    2001 Recombinant GABAC receptors expressed in rat hippocampal neurons after infection with an adenovirus containing the human ρ1 subunit 2001
    2000 Regulation of recombinant γ-aminobutyric acid (GABA)(A) and GABA(C) receptors by protein kinase CMolecular Pharmacology.  57:847-856. 2000
    1999 Evidence for phosphorylation-dependent internalization of recombinant human ρ1 GABA(C) receptors 1999
    1996 Calcium-induced inactivation of NMDA receptor-channels evolves independently of run-down in cultured rat brain neurones. 1996
    1996 [Properties of reversible Ca2+-dependent inactivation of NMDA receptor on the cerebellum granular cells].Доклады Академии Наук / Doklady Biological Sciences.  350:131-134. 1996
    1995 Calcium-dependent inactivation of heteromeric NMDA receptor-channels expressed in human embryonic kidney cells. 1995
    1994 Kainate-induced inactivation of NMDA currents via an elevation of intracellular Ca2+ in hippocampal neurons.Journal of Neurophysiology.  72:456-465. 1994

    Research Overview

  • I have a broad background in cancer biology and neuroscience with specific training and expertise in i) characterization of the cellular kinome and cytoskeleton involved in GABA and Glutamate receptor regulation in normal and pathological conditions; ii) identification of cell-signaling pathways involved in centrosome abnormalities and genomic instabilities in the early stages of glioma development; iii) establishment of the drug discovery axis of post-translational modifications of the mRNA binding protein HuR, whose up-regulation and multimerization are essential for brain tumor progression, iv) delineation of mechanisms of HuR protein multimerization and oncogenic function in glioma; v) establishment of the drug discovery axis of post-translational modifications of the PDL1 ligand. In the past 10 years, I have been deeply engaged in the drug-discovery effort (to include the development of high throughput alpha screen assay, high throughput cell-based bioluminescence reporter assays, target-structure based drug design, high throughput compound screening, identification of lead compounds and lead compound scaffolds, and SAR optimization). As a result of our drug-discovery effort in collaboration with the SRI, a new class of inhibitors of HuR dimerization in cancer cells was developed (the U.S. Provisional Patent Application No. 63/013,451). Identification of the key signaling pathways involved in genomic instabilities, glioma heterogeneity, and immune escape is the goal of my current research. The main outcome of my research is the development of a new chemotherapeutic scheme engaged with the adaptive arm of the immune response for glioma treatment and elimination of cell-signaling pathways leading to glioma heterogeneity. I propose to investigate one of the main causes of glioma heterogeneity and treatment resistance, intercellular gene transfer between glioma and normal host cells in glioma microenvironment, and the potential chemotherapeutic pathways of the intervention of this process.
  • Education And Training

  • Doctor of Philosophy Level Degree in Biology, Moscow State University named after M.V. Lomonosov 1994
  • UAB Neurobiology, Postdoctoral Fellowship 2021
  • Institute PASTEUR, Postdoctoral Fellowship 1997
  • INSERM U29, Postdoctoral Fellowship 1996
  • Full Name

  • Natalia Filippova